Rezolute Announces FDA Recommendation to Hold a Pre-BLA Meeting as a Precursor to Submitting a Biologics License Application (BLA) for Congenital Hyperinsulinism

The Agency reiterated its commitment to addressing unmet treatment needs for congenital and tumor-related hyperinsulinism and serving affected patient communities. The statement includes no specific action, timeline, or funding details.